Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk.
Evaluation of metabolic disturbances has had an important role in the modification of oral contraceptive formulations toward estrogen-progestin combinations with reduced adverse metabolic impact. An increasing number of interrelationships between metabolic risk factors for cardiovascular disease are being recognized, and a metabolic syndrome of disturbances has been identified with insulin resistance as a potential underlying factor. The insulin resistance syndrome includes hyperinsulinemia and impaired glucose tolerance, hypertriglyceridemia, reduced high-density lipoprotein concentrations, and hypertension. Increased concentration of a small, dense, low-density lipoprotein subtype may also be important. Depending on steroid type and dose, combined oral contraceptives may induce all the features of the insulin resistance syndrome. Reduction in estrogen dose and modification of progestin content have resulted in formulations with no adverse effect on high-density lipoprotein and blood pressure, but insulin resistance and hypertriglyceridemia remain. These are caused primarily by the estrogen component. Therefore modification of the estrogen content of oral contraceptives might result in "metabolically transparent" formulations that could conceivably afford a degree of cardiovascular protection.
Godsland
I F
IF
Wynn Institute for Metabolic Research, St. John's Wood, London, England.
Crook
D
D
D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced*; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007333:Insulin Resistance / Q000502:physiology; D008055:Lipids / Q000097:blood; D008660:Metabolism / Q000187:drug effects*
D003278:Contraceptives, Oral, Hormonal; D008055:Lipids